In the PRISM repurposing 19Q3 dataset30, PRR11 copy number of 27 breast cancer cell lines significantly correlated with sensitivity to the PI3K inhibitors pictilisib and taselisib (Fig. 7b). Here, PIK3CA is linked to breast carcinoma.